Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-28

Clinical Trial Update: Bisantrene Combination for Resistant AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a bisantrene combination in resistant acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • bisantrene (bisantrene)

Snippet

Sponsor: Sheba Medical Center | Conditions: Myelogenous Leukemia, Acute | Phase 2 | Status: UNKNOWN